Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mouse nerve growth factor for high-risk infants with abnormal general movements
ChiCTR-IPR-17012774Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of mouse nerve growth factor in traumatic brain injury (TBI) and Neurodevelopmental disorder (NDD) (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoints: Assessment of general movements, Gross motor function measure and 1 more. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
mouse nerve growth factor
03
Conditions
traumatic brain injury (TBI)Neurodevelopmental disorder (NDD)
Beyond the preview
Go deeper on ChiCTR-IPR-17012774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012774.